Anebulo Pharmaceuticals
ANEB
ANEB was delisted on the 27th of February, 2026.
11 hedge funds and large institutions have $19.2M invested in Anebulo Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 0 closing their positions.
22% more funds holding
Funds holding: 9 → 11 (+2)
9.25% more ownership
Funds ownership: 20.03% → 29.28% (+9.2%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
21% less capital invested
Capital invested by funds: $24.3M → $19.2M (-$5.16M)
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
2L
22NW LP
Seattle,
Washington
|
+$6.05M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$1.82M |
| 3 |
Morgan Stanley
New York
|
+$2.13K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$671 |
| 5 |
Wells Fargo
San Francisco,
California
|
+$60 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LA
LVW Advisors
Pittsford,
New York
|
-$88.9K |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
-$88.8K |
| 3 |
BlackRock
New York
|
-$710 |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$455 |
| 5 |
BFM
Boothbay Fund Management
New York
|
-$50 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
2L
1
22NW LP
Seattle,
Washington
| $14.2M | +$6.05M | +1,703,577 | +51% |
|
|
LA
2
LVW Advisors
Pittsford,
New York
| $1.89M | -$88.9K | -25,036 | -4% |
|
|
NCM
3
Nantahala Capital Management
New Canaan,
Connecticut
| $1.43M | +$1.82M | +511,073 | New |
|
|
MP
4
Mangrove Partners
Greenwich,
Connecticut
| $1.12M | – | – | – |
|
|
IC
5
Ikarian Capital
Dallas,
Texas
| $437K | -$88.8K | -24,996 | -14% |
|
|
BFM
6
Boothbay Fund Management
New York
| $48K | -$50 | -14 | -0.1% |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| $21K | +$671 | +189 | +3% |
|
|
8
BlackRock
New York
| $20K | -$710 | -200 | -3% |
|
|
9
UBS Group
Zurich,
Switzerland
| $8K | -$455 | -128 | -4% |
|
|
10
Morgan Stanley
New York
| $2K | +$2.13K | +600 | New |
|
|
11
Wells Fargo
San Francisco,
California
| – | +$60 | +17 | +85% |
|
ANEB Hedge Fund Activity: Q3 2022 in Review
11 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Anebulo Pharmaceuticals (ANEB) for Q3 2022, worth a combined $19.2M — down 21% from $24.3M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new ANEB positions and 0 closed out — a net gain of 2 holders — while 3 added to existing stakes and 5 trimmed.
The largest buyer was 22NW LP, adding an estimated $6.05M. The largest seller was LVW Advisors, cutting an estimated $88.9K.
- 11 institutional investors held Anebulo Pharmaceuticals (ANEB) as of Q3 2022, up from 9 in Q2 2022.
- Funds reported $19.2M of Anebulo Pharmaceuticals stock for Q3 2022, down 21% quarter-over-quarter.
- 2 funds opened new Anebulo Pharmaceuticals positions in Q3 2022 and 0 closed out, a net change of +2 holders.
- The largest Anebulo Pharmaceuticals buyer in Q3 2022 was 22NW LP, an estimated $6.05M added.
- The largest Anebulo Pharmaceuticals seller in Q3 2022 was LVW Advisors, an estimated $88.9K sold.
Based on aggregated 13F filings for Q3 2022.